Project RD-CURE FP3 – Bringing Gene Supplementation Therapy for Inherited PDE6A- and CNGA3-associated Retinopathies into…

Basic data

Acronym:
RD-CURE FP3
Title:
Bringing Gene Supplementation Therapy for Inherited PDE6A- and CNGA3-associated Retinopathies into Clinical Practice: A joint Tübingen-München Project
Duration:
01/10/2016 to 31/12/2019
Abstract / short description:
The goal of the RD-CURE project is to develop and establish supplemental gene therapy for i) CNGA3-linked achromatopsia and ii) PDE6A-associated retinal dystrophies including first phase I/II safety and efficacy trials in human patients.
Keywords:
gene therapy
Gentherapie
Retina
retina, Netzhaut
eye

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Center for Ophthalmology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Tübingen, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.